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Summary
In human mitochondria, transcription termination events at a G-quadruplex region near the 
replication origin are thought to drive replication of mtDNA by generation of an RNA primer. This 
process is suppressed by a key regulator of mtDNA – the transcription factor TEFM. We 
determined the structure of an anti-termination complex in which TEFM is bound to transcribing 
mtRNAP. The structure reveals interactions of the dimeric pseudonuclease core of TEFM with 
mobile structural elements in mtRNAP and the nucleic acid components of the EC. Binding of 
TEFM to the DNA forms a downstream “sliding clamp”, providing high processivity to the 
elongation complex. TEFM also binds near the RNA exit channel to prevent formation of the RNA 
G-quadruplex structure required for termination and thus synthesis of the replication primer. Our 
data provide insights into target specificity of TEFM and mechanisms by which it regulates the 
switch between transcription and replication of mtDNA.
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Crystal structures of the human mitochondrial transcription factor TEFM with its C-terminal 
domain bound to a transcription elongation complex provide insights into the molecular basis of 
its roles in promoting elongation and preventing termination.
Introduction
In human mitochondria, the process of replication of mtDNA is directly linked to 
transcription (Asin-Cayuela and Gustafsson, 2007; Gustafsson et al., 2016). In the absence 
of a dedicated mitochondrial primase, replication primers are generated by the mitochondrial 
RNA polymerase (mtRNAP), a single subunit enzyme that resembles phage RNAPs 
(Gustafsson et al., 2016; Phillips et al., 2017; Ringel et al., 2011; Wanrooij et al., 2008). The 
early replication events in human mitochondria require assembly of the transcription 
initiation complex at the light strand promoter (LSP) (Morozov et al., 2015) and termination 
of transcription after synthesis of a ∼120 nt RNA transcript to produce the primer necessary 
to initiate mtDNA synthesis (Chang and Clayton, 1985). This termination event is triggered 
by a conserved G-rich sequence, called CSBII, which is located near the replication origin 
OriH and encodes a short G-quadruplex structure (Wanrooij et al., 2012; Wanrooij et al., 
2010).
Recently, a mitochondrial transcription elongation factor, TEFM, was shown to efficiently 
prevent termination at CSBII (Agaronyan et al., 2015; Posse et al., 2015). TEFM is a 
processivity factor required for synthesis of long, near genome-size polycistronic transcripts 
by the otherwise non-processive mtRNAP (Agaronyan et al., 2015; Minczuk et al., 2011). It 
has been suggested that TEFM can serve as a key regulator involved in the molecular switch. 
TEFM would regulate whether a mitochondrial nucleoid undergoes replication (in the 
absence of TEFM) or transcription (in the presence of TEFM) and help to avoid head-on 
collisions between the replisome and the elongating mtRNAP (Agaronyan et al., 2015).
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In this work, we present the atomic structures of human TEFM domains and define their 
roles in transcription elongation and anti-termination at the CSBII site. We have also 
determined the structure of the functionally relevant TEFM C-terminal domain bound to the 
elongation complex (EC) of mtRNAP, which explains how TEFM enhances transcription 
processivity. These structural data together with the functional experiments and cross-linking 
analysis suggest the mechanisms that TEFM exploits to regulate transcription elongation and 
anti-termination.
Results
TEFM contains two structured domains
Our initial crystallization trials did not produce crystals of full-length TEFM. Sequence 
based homology prediction suggested that human TEFM contains at least two regions with 
distinct structural organization (Minczuk et al., 2011), possibly interspersed by less well-
ordered domains (Figure 1A). Protease treatment is known to improve chances of 
crystallization of proteins with flexible regions (Dong et al., 2007). We therefore probed 
whether TEFM contains unstructured regions that may interfere with its crystallization by 
using limited proteolysis with trypsin, LysC and ArgC proteases. These experiments 
revealed two stable regions representing the N-terminal domain (NTD, ∼10 kDa) and the C-
terminal domain (CTD, ∼26 kDa) of TEFM, while the region between these domains (the 
inter-domain linker) was sensitive to proteolysis (Figure S1A).
Limited proteolysis of TEFM with ArgC prior to crystallization yielded large well-
diffracting crystals of the CTD. The structure was subsequently solved at 1.9 Å resolution by 
single-wavelength anomalous diffraction (SAD) using selenomethionine-labelled protein 
(Table S1, Figure S1B,C). The TEFM CTD crystals belong to space group C2 and contain 
four molecules in the asymmetric unit with only minor differences between the individual 
molecules (Cα RMSD < 1 Å over 200 residues). To obtain the crystal structure of the TEFM 
NTD, we expressed this domain separately and obtained large, rod-like crystals of space 
group P43212 containing one molecule in the asymmetric unit. The structure of the NTD 
was solved at a resolution of 1.3 Å using the anomalous signal of the naturally occurring 
sulphur atoms (native-SAD) (Table S1, Figure S1D). The crystal structures of the NTD and 
the CTD were refined to free R-factors of 19.7 and 22.8, respectively, and both showed 
excellent stereo chemical quality (Table S1).
Structure of TEFM
In the two crystal forms, we observed interpretable electron density for residues 57-134 
(NTD) and residues 153-356 (CTD), which comprise 87% of the full-length, mature TEFM 
(Table S1). Our structures lack 21 N-terminal residues, 3 C-terminal residues, and a 19-
amino acid linker region, which connects the two domains. The linker contains six lysine 
and two arginine residues and appears to be disordered in the CTD structure. The TEFM 
CTD forms a dimeric assembly of monomers containing an RNase H-like fold that is 
characteristic of members of the Holliday junction resolvase family of enzymes (Figure 
1B,C, S1B) (Wyatt and West, 2014). This family includes a large number of RuvC-like 
resolvases from bacteria, viruses, and mitochondria (Ariyoshi et al., 1994; Gorecka et al., 
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2013; Oram et al., 1998). Structural alignment suggests that the closest structural homolog 
to the TEFM CTD is Schizosaccharomyces pombe mitochondrial Holliday junction 
resolvase, Cce1 (Ydc2) (Ceschini et al., 2001). While TEFM and Cce1 share little in 
sequence homology, the structures contain a common core fold consisting of five β-strands 
and four C-terminal helices (Figure 1D, S1B). Compared to Cce1, TEFM lacks a protruding 
three-helix region, and two N-terminal helices and two loops (α12-α13; α13-α14) are 
expanded (Figure 1D) (Sigala and Tsaneva, 2003). Similar to Cce1, dimerization of the 
TEFM CTD is mediated by a hydrophobic interface mainly formed by a contact between the 
α10 helices (residues 244–266) from the two CTD monomers.
A unique feature of TEFM, not observed thus far in any related bacterial or mitochondrial 
Holliday junction resolvase, is the presence of a compact globular N-terminal domain 
(Figure 1B). The structure of the NTD reveals that this domain adopts a tandem helix-
hairpin-helix fold ([HhH]2) found in a number of DNA binding proteins. HhH domains have 
been implicated in non-sequence-specific double stranded DNA binding and have been 
found in bacterial and eukaryotic transcription factors and other DNA binding proteins 
(Close et al., 2011; Johnson et al., 2008). Although lacking apparent sequence homology, the 
TEFM NTD superimposes well with the HhH domain of the bacterial Tex protein (Cα 
RMSD = 1.4 Å over 56 residues, PDB 3BZC) (Figure 1E). Taken together, TEFM exhibits a 
previously unseen combination of distinct structural domains – the Holliday junction 
resolvase-like CTD core flanked by two globular HhH domains.
Functional role of TEFM domains
TEFM has been previously implicated in anti-termination activity and was shown to affect 
mtRNAP stability and processivity (Agaronyan et al., 2015; Minczuk et al., 2011; Posse et 
al., 2015). To determine the functional role of TEFM domains in these activities, we 
constructed variants representing the CTD alone (Δ159 TEFM, residues 160-360), the CTD 
with a part of the linker (Δ144 TEFM, residues 145-360) and the CTD with the linker (Δ135 
TEFM, residues 136-360) (Figure 2A). In the anti-termination assay, transcription of 
template DNA containing the CSBII region results in termination of RNA synthesis by 
mtRNAP in the absence of TEFM, whereas its addition results in accumulation of run-off 
products (Figure 2B, lanes 1-4). We found that the NTD of TEFM is not required for anti-
termination activity (Figure 2B, lanes 5-7). Removal of 10 amino acids of the linker along 
with the NTD results in significant loss of anti-termination activity (Figure 2B, lanes 8-10), 
while deletion of the entire linker subdomain abolished anti-termination (Figure 2B, lanes 
11-13). TEFM variants containing single or multiple substitutions in the linker were 
defective to various extents in anti-termination activity, and substitution of amino acid 
residues 149-153 resulted in loss of activity (Figure 2C, D). We therefore conclude that the 
inter-domain linker is required for anti-termination activity of TEFM.
We next analyzed which part of TEFM affects its ability to stabilize the EC (Figure 2E). In 
this assay, ECs are halted 35 bp downstream from a promoter (in the absence of CTP) for 60 
min prior to a “chase” to run-off transcription. In the absence of TEFM, halted ECs are not 
stable and accumulation of 35-mer RNA product is observed (Figure 2E, lane 1). Addition 
of TEFM, however, results in stabilization of the EC, prevents high mtRNAP turn-over and, 
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consequently, causes nearly complete extension of 35 nt RNA to run-off (Figure 2E, lanes 
2-3). As in the experiments described above, deletion of the NTD did not affect TEFM 
stabilization activity (Figure 2E, lanes 4-5), while loss of both NTD and inter-domain linker 
rendered TEFM incapable of EC stabilization (Figure 2E, lanes 6-7). Finally, we examined 
whether the TEFM variants were able to support mtRNAP processivity on long templates 
(Figure 2F). In the absence of TEFM, mtRNAP is not able to produce detectable 4,000 nt 
long run-off RNA products. In contrast, run-off synthesis was observed in the presence of 
TEFM or TEFM variants lacking the NTD (Figure 2F, lanes 2-3). In the presence of TEFM 
CTD, mtRNAP was still able to generate long RNA transcripts, suggesting that the CTD, 
even without the inter-domain linker, is sufficient for stimulating processivity (Figure 2F, 
lane 4).
Structure determination of TEFM-mtRNAP elongation complex
To obtain the crystal structure of an anti-termination complex, in which elongating mtRNAP 
is bound to TEFM, we first defined the topology of the nucleic acid scaffold in the EC by 
RNase I and DNase I foot-printing (Figure 3A). In the absence of TEFM no clear RNA 
footprint was detected, likely due to the relative instability of the halted ECs. In contrast, in 
the presence of TEFM, a distinct footprint of about 19 nt of protected RNA was observed 
suggesting that TEFM stabilizes the EC by interacting with the 5′ end of the exiting 
transcript (Figure 3A). Removal of the NTD did not significantly alter the TEFM footprint, 
identifying the CTD and the linker domain as primary RNA-interacting regions (Figure S2A, 
B).
TEFM has previously been shown to interact with the DNA in the EC (Agaronyan et al., 
2015). To determine the TEFM footprint on DNA, we assembled ECs using an RNA-DNA 
scaffold and probed TEFM protection by DNase I (Figure 3B). In the presence of TEFM the 
protected region was significantly larger than for the EC alone, and included about 12 bp of 
upstream DNA and 14 bp of downstream DNA (Figure 3B, C). We did not detect any 
changes in DNA protection when the Δ135 TEFM variant was used, suggesting that the 
NTD does not strongly associate with DNA (Figure S2C). However, the TEFM variant 
lacking both NTD and the linker did not produce a clear DNA foot-print (Figure S2D). 
Overall, binding of TEFM to the EC significantly increases the region of nucleic acid 
protection (Figure 3C), consistent with our previous findings (Agaronyan et al., 2015).
To crystallize the anti-termination complex, we used the Δ135 variant of TEFM, which is 
fully functional in anti-termination assays, and Δ150 mtRNAP assembled into an EC on an 
RNA-DNA scaffold derived from the foot-printing experiments above. Crystals of the EC-
TEFM complex belonged to space group C2, contained two copies of the EC-TEFM 
complex in the asymmetric unit and diffracted to 3.9 Å resolution. The structure was solved 
by molecular replacement and could be refined to a free R-factor of 27.6 % (Table S2, 
Methods).
Architecture of the TEFM-mtRNAP elongation complex
The structure revealed that the TEFM CTD dimer forms an extensive network of interactions 
with all components of the EC by binding mtRNAP at the open side of the RNA-DNA 
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hybrid cavity (Figure 4 A, B). The primary point of interaction between mtRNAP and 
TEFM is the intercalating hairpin (Figure 4C), a mobile element in the N-terminal domain of 
mtRNAP involved in separation of RNA from the RNA-DNA hybrid and thus maintenance 
of the trailing edge of the transcription bubble (Schwinghammer et al., 2013). Two invariant 
aromatic residues in the intercalating hairpin, Y610 and F612, and the conserved residue 
Q617 project into a hydrophobic cleft on the surface of TEFM, the walls of which are 
formed by helices adjacent to the β-strand core (Figure 4C).
The structure of the EC-TEFM complex reveals that the homodimeric form of TEFM 
observed in the CTD crystals also occurs when TEFM is bound to mtRNAP (Figure 4A, B). 
To investigate whether dimerization of TEFM is required for its activity, we modified the 
hydrophobic interface between the TEFM monomers to prevent their association by 
substituting five residues in the α10 helix (Figure S3A). In contrast to the wild type TEFM, 
the resulting protein eluted as a monomer during size exclusion chromatography and did not 
bind to the EC (Figure S3B). No anti-termination activity was observed with the mutant 
monomeric TEFM, confirming that dimerization of TEFM is required for its activity (Figure 
S3C).
TEFM makes extensive interactions (∼1000 Å2) with the downstream DNA duplex of the 
EC. The positively charged surface of one of the TEFM monomers covers the otherwise 
exposed DNA and along with mtRNAP sequesters it in a fashion resembling the DNA 
“clamping” observed in multi-subunit eukaryotic and bacterial RNAPs (Figure 4D, S4A, B). 
This clamping may explain the stabilization and higher processivity of ECs in the presence 
of TEFM (Agaronyan et al., 2015). The positively charged TEFM surface extends to the 
other monomer contributing to a much smaller interaction surface with the upstream than 
with the downstream DNA (Figure S4A, B). Consequently, the electron density for the 
downstream DNA duplex was strong, whereas the density for the upstream DNA duplex was 
weaker due to higher conformational flexibility (Figure S4C). Furthermore, we observed 
difference density corresponding to the single-stranded region of the DNA non-template 
strand in the transcription bubble, which wraps around the opposite side of the dimer axis of 
TEFM formed by the α10 helices (Figure S4C). This region of the DNA was invisible in the 
previous structure of the EC (Schwinghammer et al., 2013) due to conformational flexibility 
but seems to be stabilized in the EC-TEFM complex. However, we refrained from modelling 
it due to the limited resolution of the complex structure. Thus, in addition to interacting with 
the downstream DNA, TEFM also stabilizes the EC by sequestering the single-stranded 
portion of the non-template strand of DNA (Figure 4D). Although visible only partially in 
the EC-TEFM structure, both inter-domain linkers of TEFM are located in close proximity 
to the DNA suggesting that the NTDs of TEFM may reside near or at the downstream and 
upstream duplexes (Figure 4D). Thus, it is plausible that the positively charged residues in 
the linker contribute additional interaction points with the upstream and downstream DNA, 
thereby anchoring TEFM to the EC (Figure 4D). This could be important for the anti-
termination activity because binding of TEFM to the EC must outweigh the energetically 
favorable formation of stable secondary structure such as a G-quadruplex. Indeed, 
substitutions of the charged residues in the linker region or its deletion have a profound 
effect on transcription anti-termination, as demonstrated above (Figure 2).
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Implications for mtRNAP translocation
Binding of TEFM to the EC does not cause noticeable structural changes in the elongation 
factor (Cα RMSD = 0.48 Å over 389 residues). Superimposition of mtRNAP in the EC and 
the EC-TEFM complex reveals that the C-terminal catalytic domain remains unchanged, 
whereas the PPR domain and the N-terminal core domain are slightly rotated outwards and 
the “fingers” domain adopts a markedly different orientation (Figure 4A, Figure S4D). The 
latter, however, is not caused by TEFM binding per se, as the observed changes are 
attributed to the different translocational state of mtRNAP. Indeed, the ‘n+1’ template strand 
base in the EC-TEFM complex is not paired to the corresponding non-template strand base 
and instead is found in a “pre-insertion” site of mtRNAP, indicative of the post-translocated 
state of the EC (Figure 4D) (Temiakov et al., 2004). The O/Y helices of the fingers domain 
are rotated ∼15°, respectively, as compared to the pre-translocated complex 
(Schwinghammer et al., 2013), and thus the active site of mtRNAP is found in the “open” 
conformation, previously observed in T7 RNAP ECs (Figure 4E, F) (Tahirov et al., 2002; 
Yin and Steitz, 2002). Overall, the conformation of the fingers domain and the position of 
the 3′ end of RNA in mtRNAP closely matches those in the T7 RNAP post-translocated 
complex. Comparison of the available structures of mtRNAP (the apo form, pre-translocated 
EC and post-translocated EC) suggests a rotation of the O/Y helices around an axis that is 
nearly parallel to the O helix (Figure 4G). This rotation allows for delivery of the cognate 
substrate bound to the n+1 template base into the insertion site and the closing of the active 
site required for catalysis (Temiakov et al., 2004; Yin and Steitz, 2004). The mechanism of 
translocation therefore appears to be highly conserved between mitochondrial and phage 
RNAPs.
Considering the conformational changes in mtRNAP observed in the EC-TEFM structure, 
we employed a pyrophosphorolytic assay to probe whether TEFM can affect the 
translocation state of the EC (Figure 4H). Pyrophosphate binds only to ECs in which 
mtRNAP is in a pre-translocated conformation and drives reaction that is reverse to RNA 
synthesis. In the absence of TEFM, RNA was readily shortened by 2 nucleotides, suggesting 
pyrophosphorolytic activity of this EC (Figure 4H, lanes 3-7). In contrast, in the presence of 
TEFM the sensitivity of the EC was significantly decreased suggesting stabilization of the 
post-translocated state, consistent with our structural observations (Figure 4H, lanes 9-13).
Mapping of TEFM-mtRNAP interactions by cross-linking
Since interactions between mtRNAP and TEFM may involve structural elements that are 
mobile and thus only partially visible in the EC-TEFM structure, we set to map them using 
an array of cross-linking methods coupled with mass spectrometry, chemical mapping, and 
mutational analysis. We employed a long range cross-linker BS3 
(bis(sulfosuccinimidyl)suberate, 11.4 Å), a medium range cross-linker DSG (disuccinimidyl 
glutarate, 7.7 Å), a short-range cross-linker p-benzoyl-phenylalanine (Bpa, <4 Å) and a 
“zero-length” cross-linker EDC (1-ethyl-3-(3-dimethylaminopropyl)carbodiimide) (Leitner 
et al., 2010; Morozov et al., 2015).
Mass spectrometry analysis of the long-range cross-links obtained with BS3 and DSG 
revealed proximity of the inter-domain linker (residues K144, K153 and K156) of TEFM 
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(Figure 5A, S5A) to the specificity loop (residues K1087 and K1089) of mtRNAP - a 
structural element implicated in promoter specificity and formation of the RNA exit pore in 
single subunit RNAPs (Schwinghammer et al., 2013; Temiakov et al., 2000). We also 
detected a single interaction point between functionally important TEFM domains (CTD/
linker) and mtRNAP (Figure 5A) using the EDC “zero-length” cross-linking, which relies on 
modification of D-K and E-K salt bridges (Rivera-Santiago et al., 2015). This interaction 
involves surface residue E214 (or E215) in TEFM and the exposed residue K1089 in the 
specificity loop of mtRNAP. To confirm these findings and to further map the interaction 
interface, we used the photo reactive amino acid Bpa incorporated into different positions 
within mtRNAP (Figure 5B, S5B). Consistent with the EDC cross-linking data, we found 
that substitution of residues V1088 and I1091 in the specificity loop of mtRNAP resulted in 
efficient cross-linking with TEFM (Figure 5B). In addition, we detected a strong cross-link 
(∼30%) to TEFM when Bpa was placed at position 610 in the intercalating hairpin of 
mtRNAP, in agreement with the structural data (Figure 5B, 4C). Both the specificity loop 
and the intercalating hairpin are found in close proximity to each other in the EC, and 
although the tip of the specificity loop is not fully resolved in the EC-TEFM structure, it can 
be confidently placed in proximity to TEFM based upon RNA-mtRNAP cross-linking data 
(Figure 5D) (Schwinghammer et al., 2013).
To refine the interaction interface between mtRNAP and TEFM, we used a reciprocal 
approach and incorporated the Bpa probe into various positions in TEFM (Figure 5C, 
S5B,C). We detected efficient cross-linking when Bpa was positioned in an unstructured, 
solvent exposed loop (the “docking loop”, residues 305-315) at the distal end of the CTD 
dimer (Figure 5D). There, several TEFM Bpa variants (Bpa308, 309, 310, and 312) 
produced efficient (>30%) cross-linking to mtRNAP, suggesting an additional point of 
interaction between the two proteins (Figure 5A, C). We found that 308Bpa TEFM cross-
links to two regions of mtRNAP that involve residues 120-150 in the N-terminal extension 
region of mtRNAP (65% of the cross-link) and residues 364-602, located in the palm 
subdomain, near to the PPR domain (35% of the crosslink) (Figure S6A-G).
Interestingly, the region 120-150 in mtRNAP (not present in the mtRNAP construct used to 
determine the EC-TEFM structure) constitutes the binding site for transcription initiation 
factor TFAM (Morozov et al., 2014), suggesting that binding of TEFM contributes to the 
transition from the initiation to the elongation phase of transcription. To demonstrate that 
TEFM binding is specific to the elongation phase of transcription, we assembled different 
transcription complexes - the pre-initiation complex, the initiation complex and the EC - 
using Bpa-modified mtRNAP variants (Figure 5E, F). Efficient cross-linking between 
mtRNAP and TEFM was only observed when the EC was formed (Figure 5E, F). In 
agreement with these data, analytical size exclusion chromatography demonstrated that 
TEFM does not efficiently bind to the initiation complex (Figure S5D, E). To conclude, the 
cross-linking data above corroborate the EC-TEFM structure and expand the comprehensive 
map of interactions between TEFM and mtRNAP during transcription elongation.
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Mechanisms of transcription termination and anti-termination at CSBII
Human mtDNA encodes a G-rich sequence followed by an 8 bp “spacer” region and a 9 bp 
AU-rich region that precedes the termination point and constitutes the RNA-DNA hybrid in 
the EC (Figure 6A). CD spectroscopy experiments have confirmed that the G-rich region in 
RNA is sufficient to form a strong G-quadruplex structure (Wanrooij et al., 2012), which 
may fold into a parallel-stranded structure having three G-tetrad layers (Figure 6B) 
(Mukundan and Phan, 2013). The spacer region appears to be dispensable as it can be 
removed without affecting efficiency or site of termination (Figure 6C). However, when the 
AT-rich region in the CSBII sequence was changed to a GC-rich region, no termination was 
observed at the usual point, suggesting the importance of the weak RNA-DNA hybrid in 
transcription termination at CSBII. (Figure 6D). Instead, multiple points of termination 
downstream of the usual termination site were observed, all of which corresponded to the 
occurrence of U-stretches in the RNA (Figure 6D). This indicates that efficient termination 
at CSBII depends on the formation of a G-quadruplex at the point at which it is most 
disruptive to the EC (i.e. in proximity to the RNA-DNA hybrid). Termination at the G-
quadruplex in human mitochondria is therefore reminiscent of transcription termination in 
bacteria and T7-like phages, where secondary structure in the RNA (hairpin) is thought to 
destabilize the EC and a U-stretch is required for its disruption (Epshtein et al., 2007; 
Gusarov and Nudler, 1999; Ma et al., 2005).
The structure of the anti-termination complex combined with cross-linking and RNase foot-
printing data suggests that TEFM binds near the RNA exit channel and “guides” the 
emerging transcript from the region of its separation from the DNA to the point where RNA 
reaches a length of about 18-20 nucleotides (Figure 2,3,4,6). TEFM interacts with two 
mobile elements in mtRNAP - the intercalating hairpin and the specificity loop (Figure 
5B,D), which were shown to contribute critically to EC stability (Schwinghammer et al., 
2013). Modeling of an RNA G-quadruplex into the EC structure suggests that this bulky 
secondary structure would clash with both the specificity loop and the intercalating hairpin 
(Figure 6E). This would likely result in displacement of these elements and pulling of RNA 
from the active site, thus causing dissociation of mtRNAP from the DNA (Figure 6E). In 
contrast, binding of TEFM to the intercalating hairpin and specificity loop occludes the 
space in the EC where formation of the G-quadruplex would have the most dramatic impact 
on the complex stability (Figure 6F). Interestingly, mtRNAP does not efficiently terminate at 
hairpin termination signals, such as bacterial TrpA and T7 terminator TΦ (Figure S6), 
possibly due to the relatively small size of these hairpins (∼23Å in diameter vs. ∼36 Å for 
the G-quadruplex), which may not be sufficient to disrupt mtRNAP elements at the point of 
termination (Figure 6E, F).
Discussion
The bipartite role of TEFM in transcription elongation and anti-termination
The structure of the anti-termination complex explains how TEFM increases the processivity 
of mtRNAP. First, TEFM enhances interaction of the EC with the downstream DNA, 
contributing to a sliding clamp, a characteristic feature of a processive polymerase. Second, 
TEFM sequesters the single-stranded portion of the non-template DNA strand, thus 
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preventing collapse of the transcription bubble. Third, because of the binding of TEFM to 
the specificity loop and the intercalating hairpin, which contributes to the formation of the 
RNA exit channel, the anti-termination complexes possess a much higher stability and 
processivity, as required for syntheses of genome-size RNA transcripts. Finally, TEFM may 
stabilize the post-translocation state of the EC, which is known to enhance RNAP 
processivity by promoting forward translocation and preventing pausing and arrest of 
transcription complexes on various sequences (Herbert et al., 2010).
The G-rich sequence found in CSBII is predicted to form a G-quadruplex structure and is 
likely the major cause of EC destabilization leading to termination of RNA synthesis and 
primer formation for mtDNA replication. Two hypotheses involving the nature of the G-
quadruplex in human mitochondria have been advanced – that formation of the quadruplex 
involves a hybrid between the NT DNA strand and the RNA and, alternatively, that the 
quadruplex involves only RNA (Wanrooij et al., 2012; Wanrooij et al., 2010). Analysis of the 
mtRNAP EC structure suggests that formation of the hybrid quadruplex structure is highly 
unlikely due to steric hindrance provided by mtRNAP, which separates the RNA from the 
DNA-RNA hybrid and diverts it away from the upstream DNA (Schwinghammer et al., 
2013). Consistently, substitution of GMP to 7-deazaGMP (which disrupts G-quadruplex 
formation) in DNA does not affect termination at CSBII, suggesting that a RNA quadruplex 
is solely responsible for termination (Kuzmine et al., 2001; Wanrooij et al., 2012).
The efficiency of termination at CSBII has been demonstrated to depend upon the 
arrangement of the G residues in this region, which is highly polymorphic in the human 
mtDNA population. Thus, the more commonly occurring sequences - G6AG8 and G6AG7 
(30% of the population) - exhibit significantly higher efficiency of termination as compared 
to the relatively rare G5AG8 and G5AG6 sequences (Kang et al., 2016; Tan et al., 2016). 
This suggests that the strength of the G-quadruplex is likely a primary contributor to the 
efficiency of transcription termination and thus to replication and maintenance of mtDNA 
copy number (Agaronyan et al., 2015). The more common G-quadruplex sequences in 
human mtDNA allow assembly similar to a three-layer G-quadruplex structure having a 
single nucleotide insertion (bulge) (Mukundan and Phan, 2013)(Figure 6B). This would 
result in a bulky structure forming inside the RNA exit channel of mtRNAP, likely causing 
disruption of the EC. Lack of termination of mtRNAP at hairpin terminators, at which a 
related T7 RNAP efficiently terminates, suggests that weaker secondary structures are 
tolerated by mtRNAP. This phenomenon may be attributed to the biological role of 
mtRNAP, which must transcribe through extensive secondary structures of ribosomal and 
transfer RNAs. The structure of the anti-termination complex reveals that TEFM binds at the 
junction between the RNA-DNA hybrid and the upstream DNA, near the RNA exit channel 
(Figure 4A, B). This is predicted to prevent formation of the G-quadruplex structure near the 
point of RNA separation from the RNA-DNA hybrid, the mtRNAP region that defines EC 
stability. Formation of the G-quadruplex past this point would not impose as dramatic an 
effect on EC stability and, as consequence, cause efficient termination (Figure 6D). The anti-
termination mechanism for TEFM is thus reminiscent to that of the phage lambda protein N 
and bacterial transcription factor RapA, both of which bind at the RNA exit channel and 
prevent RNA hairpin formation within the bacterial RNAP EC (Gusarov and Nudler, 2001; 
Liu et al., 2015).
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TEFM as a dedicated transcription factor
Since the TEFM CTD shows high structural similarity to RuvC-like resolvases, the question 
as to whether it possesses a nuclease activity may have significant bearings on the 
mechanism of replication in human mitochondria. Indeed, the closest structural homologs of 
TEFM, S.p. and S.c. Cce1, are functional resolvases (Doe et al., 2000; Lockshon et al., 
1995). Yeast cells deficient in Cce1 exhibit a dramatic increase in mtDNA aggregation (Doe 
et al., 2000; Piskur, 1997). The crystal structure of the TEFM CTD dimer reveals two 
putative nuclease sites, which are similar in overall shape to the active sites of Cce1 (Figure 
7A, B). S.p. Cce1 uses three negatively charged catalytic residues (D320, E117 and D46) to 
coordinate Mg ions required for nuclease activity (Ceschini et al., 2001). In TEFM, the two 
corresponding residues, D342 and E232, are preserved; however, the third catalytic residue 
is altered to valine (V174), which is conserved in TEFM from all species (Figure 7A,B). The 
structure suggests that this substitution renders TEFM unable to coordinate a Mg ion. 
Indeed, no electron density compatible with a bound divalent cation was observed in our 
structure even though crystallization conditions included 200 mM MgCl2. We therefore 
conclude that the nuclease sites in TEFM are degenerate and not functional. Indeed, 
considering that mammalian mitochondrial genomes are among the smallest, it is plausible 
that during evolution and transfer of many mitochondrial genes to the nucleus the resolvase 
function became non-essential for mtDNA maintenance. In contrast, preservation of a 
functional Holliday junction resolvase in yeast mitochondria is related to its essential 
function during replication, as the heritable mtDNA units in S. cerevisiae consist of genomes 
linked via recombination junctions (Doe et al., 2000; Lockshon et al., 1995). Although 
lacking nuclease activity, TEFM evolved to retain the ability of a Holliday junction resolvase 
to bind DNA, as the protein establishes simultaneous contacts with the RNA-DNA hybrid 
duplex and the downstream and upstream DNA regions of the transcription bubble (Figure 
4A, B, D). These three duplexes of the EC are sharply bent relative to each other and 
resemble the topology of the DNA junctions, at which RuvC-like resolvases operate 
(Gorecka et al., 2013).
Target specificity of TEFM
Many transcription factors can recognize a particular conformation of RNAP allowing for 
transient regulation of its activity (Washburn and Gottesman, 2015). This is clearly the case 
for TEFM, as the cross-linking data and analytical gel filtration assay suggest that TEFM 
can efficiently bind to the EC, but not to the pre-initiation complex, initiation complex or the 
apo mtRNAP (Figure 7C, 5E, F). Our structural data provide an explanation for this 
observation. In the EC, the orientation of the two major structural elements of mtRNAP that 
bind TEFM - the intercalating hairpin and the specificity loop - are fixed by interactions with 
the DNA and RNA (Figure 4A, B). In contrast, in the apo mtRNAP structure, both loops are 
disordered (Ringel et al., 2011) and therefore cannot contribute to the efficient binding of 
TEFM (Figure 5E, F). In the pre-IC and the IC the intercalating hairpin and specificity loop 
are likely engaged in interactions with promoter DNA and may not be fully accessible to 
TEFM (Morozov et al., 2015). Once mtRNAP completes the transcription cycle and 
dissociates from mtDNA, TEFM can no longer bind to the mtRNAP efficiently, and 
dissociates prior to engagement of mtRNAP in transcription initiation (Figure 7C).
Hillen et al. Page 11
Cell. Author manuscript; available in PMC 2018 November 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
Our data on the mechanism of TEFM anti-termination activity, EC stabilization, mtRNAP 
processivity enhancement, and target specificity provide the molecular basis for the 
proposed role of TEFM in regulation of the switch between transcription and replication in 
human mitochondria (Agaronyan et al., 2015). Future experiments should be directed 
towards deciphering whether this regulation includes post-translational modifications of 
TEFM or changes in TEFM concentration in mitochondria by expression, degradation or 
other, yet unidentified factors.
Contact for Reagent and Resource Sharing
Further information and requests for resources and reagents should be directed to and will be 
fulfilled by the Lead Contact, Dmitry Temiakov (temiakdm@rowan.edu). A Material 
Transfer Agreement will be required to fulfill the requests.
Method Details
Protein expression and purification
Human mtRNAP (Δ119 and Δ150), WT TFAM, TFB2M (Δ20), WT TEFM, and Δ50 TEFM 
were expressed and purified as described previously (Agaronyan et al., 2015; Morozov et al., 
2015; Sologub et al., 2009). Variants of these proteins were obtained by site-directed 
mutagenesis (QuikChange, Agilent) and purified as described previously (Morozov et al., 
2015). TEFM NTD (residues 36-136) was purified using cation exchange chromatography 
on a MonoS column (GE Healthcare) followed by gel-filtration on a Superdex 200 10/300 
column (GE Healthcare). Expression of Bpa-containing proteins was performed as described 
previously (Morozov et al., 2015). For expression of selenomethionine-labeled protein, 
expression cultures were grown in SeMet base media (Molecular Dimensions) with the 
addition of L-selenomethionine (50 μg/ml), L-lysine (50 μg/ml), L-threonine (50 μg/ml), L-
phenylalanine (50 μg/ml), L-leucine (25 μg/ml), L-isoleucine (25 μg/ml) and L-valine (25 
μg/ml). Selenomethionine-labeled TEFM was purified as described above.
Limited proteolysis of TEFM
TEFM was subjected to limitied proteolysis using trypsin (Sigma, protease/TEFM ratio 1: 
20,000 w/w), ArgC protease (Promega, 1:1000 w/w), LysC protease (Sigma, 1:1000 w/w) 
for 1 h at RT. Products of protease digestion of TEFM were dissolved in a solution 
containing 5% acetonitrile and 0.1% tetrafluoroacetic acid and purified using C4 ZipTip. 
The peptide mixtures were analyzed using a Bruker MicroFlex MALDI-TOF instrument in 
sinapinic acid matrix with R=5000.
Crystallization of TEFM
Purified Δ50 TEFM (6.5 mg/ml) was treated with ArgC protease (Promega, 1:1000 w/w) 
and incubated for 60 min at room temperature (RT) prior to crystallization trials. Initial hits 
were obtained using the sitting drop vapor diffusion with a well solution containing 100 mM 
BIS-TRIS pH 5.5 – 6.5, 200 mM MgCl2 and 25% PEG3350. Large, diffraction-quality 
crystals were obtained by the hanging drop vapor diffusion method by micro-seeding with 
crushed crystals into fresh drops. Crystals appeared within 24 h and grew to full size over 
Hillen et al. Page 12
Cell. Author manuscript; available in PMC 2018 November 16.
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
A
uthor M
an
u
script
the course of two weeks. Crystals were cryo-protected by gradually increasing the glycerol 
concentration to 20% (v/v) and flash frozen in liquid nitrogen.
TEFM NTD (10 mg/ml) was crystallized using the sitting drop vapor diffusion method and 
Crystallization Screen solution 15 (Hampton Research) containing 30% PEG4000, 0.2 M 
ammonium acetate, 0.1 M sodium acetate (pH 4.0) to produce large (0.05 mm × 0.05 mm × 
0.8 mm) needle-like crystals. The crystals were flash-frozen using a stabilization solution 
containing 30% PEG4000, 15% PEG400, 0.1 M ammonium acetate and 0.05 M sodium 
acetate pH 4.0.
Crystallization of the EC-TEFM complex
Synthetic DNA and RNA oligonucleotides (IDT DNA) NT25HH, TS22HH and RNA14mt 
were dissolved in H2O and mixed at a final concentration of 0.5 mM. The sequences of the 
oligos (IDTDNA) are as follows (5′ to 3′): 
GAACATGGTGTAATTATTTCGACGCCAGACGAAC (NT25HH), 
GTTCGTCTGGCGTGCGCGCCGCTACACCATGTTC (TS22HH) and 
AGUCUGCGGCGCGC (RNA14mt). The scaffold was annealed by heating the mixture to 
95°C and step-wise cooling (1°C / 90 s) to 4°C. To form an EC/TEFM complex, Δ150 
mtRNAP (45 μM) was mixed with a 1.1-fold molar excess of DNA/RNA scaffold and 
incubated at 20°C for 10 min prior to addition of a 2.2-fold molar excess Δ135 TEFM and 
further incubation at 20°C for 10 min. The complex was subsequently purified by size 
exclusion chromatography using a Superdex 200 Increase 3.2/300 column (GE Healthcare) 
equilibrated with buffer containing 10 mM Tris-HCl pH 8.0, 100 mM NaCl, 20 mM MgCl2, 
10 mM DTT, 1 mM Tris(2-carboxyethyl)phosphine and 5 % (v/v) Glycerol. Peak fractions 
were pooled and used for crystallization. Crystals were obtained by the hanging-drop vapour 
diffusion method by mixing 2.5 μl of protein complex solution with 2.5 μl of reservoir 
solution containing 100 mM BIS-TRIS pH 5.5, 200 mM (NH4)2SO4, 6% PEG3350 and 0.5 
μl of a seeding solution prepared from crystals previously obtained in an identical condition. 
Crystals appeared as thin blade clusters after 3-4 days. The clusters were carefully broken 
into individual blades and cryo-protected by gradually increasing the glycerol concentration 
in the drop to 25% (v/v) final prior to fishing and freezing in liquid nitrogen.
Structure determination, model building and refinement
Diffraction data for TEFM CTD and EC-TEFM complex crystals was collected at beamlines 
X06SA and X10SA at the Swiss Light Source (Villigen, CH) using a Pilatus 6M detector. 
Diffraction data for TEFM NTD crystals was collected at beamline P13 at the PETRA III 
storage ring operated by EMBL (DESY, Hamburg, Germany). Data were indexed and 
integrated using XDS and scaled using XSCALE (Kabsch, 2010). Anomalous substructure 
determination, phasing and density modification was performed using the hkl2map interface 
and SHELXC/D/E (Pape and Schneider, 2004; Sheldrick, 2008), as well as phenix.autosol 
(Adams et al., 2010). To obtain experimental phase information for the TEFM CTD crystals, 
multiple datasets from two isomorphous selenomethionine-containing crystals were merged 
using XSCALE and used for SAD phasing. Heavy atom sites identified by SHELXD were 
manually edited to remove weak occupancy sites and used as input in phenix.autosol for 
phasing and density modification. The obtained electron density map was of excellent 
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quality and allowed for manual building of most of the four protein chains in the asymmetric 
unit (Figure S1 C). Refinement was carried out against the high-resolution native dataset 
using phenix.refine (Adams et al., 2010) and alternated with manual adjustment in Coot 
(Emsley et al., 2010) until a model with excellent stereochemistry was obtained. 
Experimental phase information for TEFM NTD crystals was obtained in a SAD experiment 
utilizing native sulfur atoms present in cysteine and methionine residues by collecting 
multiple highly redundant datasets from a single crystal at a wavelength of 2.066Å. Datasets 
were merged using XSCALE and substructure determination, phasing, density modification 
and phase extension was carried out with SHELXC/D/E. The resulting electron density map 
was readily interpretable and used for manual model building. The model was subjected to 
iterative rounds of refinement in phenix.refine against the high-resolution native dataset 
collected from the same crystal and manual model building in Coot until excellent 
stereochemistry and R-factors were achieved. The final mFo-DFc map displayed some 
unmodeled difference density between crystallographically related molecules, corresponding 
to unidentified solvent molecules.
The EC-TEFM structure was solved by molecular replacement in Phaser (McCoy et al., 
2007) using the human mitochondrial transcription elongation complex (PDB ID: 4BOC) 
(Schwinghammer et al., 2013) and the TEFM CTD structure as search models. The resulting 
electron density was readily interpretable and used to rigid body fit domain movements in 
mtRNAP manually in Coot. The model was subsequently refined in phenix.refine alternated 
with manual adjustment in Coot, with secondary structure restraints and reference model 
restraints enabled until the late stages of refinement due to the low resolution of the data. We 
observed positive difference density corresponding to the previously unresolved single-
stranded region of the non-template strand as well as for parts of the N-terminal extension of 
mtRNAP, which may be involved in forming crystal contacts, but refrained from de-novo 
modeling these regions due to the limited resolution. The unbiased Fo-Fc map for the non-
template strand was calculated from a model that never contained a model for the non-
template strand. The final model was refined to good stereochemistry and a free R factor of 
27.6%.
Promoter templates for transcription assays
Templates for transcription anti-termination assays containing the LSP promoter and CSBII 
region were prepared by PCR amplification as described previously (Agaronyan et al., 
2015). For the processivity assay, plasmid DNA (pT7blue) containing the LSP promoter 
region (-70/+70LSP_pT7blue) (Morozov et al., 2015) was linearized using the XhoI 
nuclease. The template was purified using phenol-chloroform extraction followed by ethanol 
precipitation. For termination assays, T7 phage terminator TΦ and bacterial terminator TrpA 
were cloned into LSP-containing plasmid (-70/+70LSP_pT7blue) 70 bp downstream of the 
transcription start site. For the halted complex assays and RNA foot-printing, a variant of the 
LSP-promoter template (“+35LSP”) with the initial transcribed sequence 
AAAGATAAAATTTGAAATGGTAGT TGTTTAAGTTGC was used.
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Transcription assays
Standard transcription reactions were carried out using PCR-amplified DNA templates (50 
nM), mtRNAP (50 nM), TFAM (50 nM), TFB2M (50 nM) in a transcription buffer 
containing 40 mM Tris-HCl pH=7.9, 10 mM MgCl2 and 10 mM DTT in the presence of 
ATP (0.3 mM), GTP (0.3 mM), UTP (0.01 mM) and 0.3 μCi[α-32P] UTP (800 Ci/mmol). 
Reactions were carried out at 35 °C for 60 min and stopped by addition of an equa l volume 
of 95 % formamide / 0.05 M EDTA. The products were resolved by 20% PAGE containing 6 
M urea and visualized using a PhosphorImager (GE Healthcare). For the processivity assay, 
the reactions (10 μl) were stopped by addition of 190 μl of stop buffer containing 20 mM 
Tris-HCl pH 8.0, 150 mM NaCl, 20 mM EDTA, 1% SDS and 20 μg/ml proteinase K. After 
incubation at 55°C for 1 h the RNA products were extracted with a phenol/chlorophorm/
isoamyl alcohol mixture followed by ethanol precipitation and resolved by 6% PAGE 
containing 6 M urea.
Nuclease foot-printing assays
For RNA foot-printing, ECs were halted 35 bp downstream of the promoter start site by 
omitting CTP from the transcription reaction and treated with RNase 1f (NEB) for 5 min at 
RT. For DNA foot-printing, the ECs were assembled using R14mt/TS36/NT36 scaffold, 
incubated for 14 min with TEFM at RT and treated with DNase I (NEB) for 5 min at RT. 
The sequences of the oligos (IDTDNA) are as follows (5′ to 3′): 
GGGCTTAGTTCGTCTGGCGTGCGCGCCGCTACAC CATGTTTGCTGACC (TS26), 
GGTCAGCAAACATGGTGTAAGTATTACGACGCCAGAC GAACTAAGCCC (NT26A). 
The reactions were stopped by addition of an equal volume of 95 % formamide/0.05 M 
EDTA and resolved by 20% PAGE containing 6 M urea.
Cross-linking using photo reactive amino acid (Bpa)
The ECs (0.5 μM) were assembled using R14mt/TS2/NT2 scaffold (Schwinghammer et al., 
2013) and mtRNAP. TEFM (1 μM) was added to the EC and incubated for 15 min at RT. 
The cross-linking was activated by UV irradiation at 312 nm for 30 min at RT.
Mapping of TEFM-mtRNAP interaction using BS3 and EDC
The EC/TEFM complex was assembled by incubating Δ150mtRNAP (10 - 20 μM) with a 
2.5-fold molar excess of WT TEFM and a 1.3-fold molar excess of RNA14HH/NT19HH/
TS16HH scaffold for 10 min at 20°C. The sequence of the oligos (IDT DNA) is as follows 
(5′ to 3′): UGAUGGUAAUGCUCCUGUCGUGAUC (RNA14HH), 
CATGGGGTAACTAGTTCGACGCCA GACG (NT19HH), 
CGTCTGGCGTGATCACGACTACCCCATG (TS16HH). The complex was subsequently 
purified by size exclusion chromatography using a Superdex 200 Increase 3.2/300 column 
(GE Healthcare) equilibrated with buffer containing 20 mM HEPES pH 8.0 for BS3 or pH 
7.5 for EDC, 100 mM NaCl, 20 mM MgCl2, and 0.5 mM Tris(2-carboxyethyl)phosphine. 
The purified complexes (∼2 μM) were then incubated with a 150 to 470-fold molar excess of 
BS3 (Thermo Fisher) for 30 min at 30°C or with 2500 to 15000-fold molar excess of EDC 
(Thermo Fisher) in the presence of 1 mM N-hydroxy-sulfosuccinimide for 60 min at 23°C. 
The reactions were quenched by the addition of 200 mM (NH4)2HCO3 followed by 
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incubation for 5 min on ice. The products of the reaction were resolved using 4 - 12% SDS-
PAGE (Invitrogen) and the cross-linked species excised and in-gel digested with trypsin. The 
tryptic peptides were extracted, dried and reconstituted in solution containing 5% v/v 
acetonitril and 0.1 % v/v FA and subjected to liquid chromatography-tandem mass 
spectrometry (LC-MS/MS). The separated peptides were analyzed online on a Q-Exactive 
HF mass spectrometer (Thermo Scientific). The raw data of LC-MS/MS analysis were 
converted to Mascot generic format files with Proteome Discoverer 2.0.0.802 software 
(Thermo Scientific) and searched against a protein database by pLink 1.22 software (Yang et 
al., 2012) as described in (Pleiner et al., 2015). The results were obtained with 1% false 
discovery rate followed by manual validation and removal of all tandem spectra that did not 
show confident sequence coverage of both cross-linked peptides.
Mapping of TEFM-mtRNAP interactions using DSG
To map the TEFM binding site, EC-TEFM complex (5 μM in 40 mM Na-HEPES pH 7.5) 
was treated with a mixture of DSG/[2H4]-DSG (0.6 mM DMSO solution, ProteoChem) and 
the products of the reaction separated using 7% Tris-glycine SDS PAGE. The cross-linked 
species were excised from the gel and subjected to trypsin digestion in 100 mM NH4HCO3 
buffer overnight at 37°C. The products of the digestion r eaction were extracted from the gel 
with CH3CN-0.1% TFA in water (9:1), dried in vacuum, re-dissolved in 10 mg/ml CHCA 
matrix in CH3CN-0.1% TFA in water (1:1), and the resulting solution applied on target for 
MALDI-TOF mass spectrometry. Mass spectra were taken on a MicroFlex LRF 
spectrometer (Bruker). Positively charged ions (M+H+) were analyzed in the reflector mode 
(m/z 1000 to 4000) and cross-linked peptides identified using xBobcat mass matching search 
engine (http://prottools.ethz.ch/orinner/public/htdocs/xquest/index_review.html) (Rinner et 
al., 2008).
Mapping of the Bpa-TEFM cross-link site in mtRNAP
For mapping with the HRV 3C protease (Pierce), the ECs were assembled using D119 
mtRNAPs with engineered 3C cleavage sites (LEVLFQGP): 3C-PPR mtRNAP (substitution 
of residues 358-364, cleaved at Q363), 3C-thumb mtRNAP (insertion after residue H745, 
cleaved at Q751) and 3C-lever-loop mtRNAP (insertion after residue K596, cleaved at 
Q602). All these mtRNAP variants also contained an engineered protein kinase (PKA) site 
at the N-terminus (MGHHHHHHRRASV…) (Morozov et al., 2015). Upon UV irradiation, 
the ECs (0.5 μM) were incubated with 3C protease (1:1 w/w ratio) for 15 - 25 h at 4 °C and 
the products of the reaction resolved using 4 - 12% SDS PAGE (Invitrogen). NTCB mapping 
of the TEFM sites in mtRNAP was performed as described in (Morozov et al., 2015). The 
TEFM-mtRNAP cross-link was excised from the gel, eluted with 0.2% SDS for 1 h at 4 °C 
and precipitated with 80% acetone. The dried material was dissolved in a solution containing 
0.2% SDS prior to the NTCB treatment. Hydroxylamine (NH2OH) cleavage was performed 
as in (Sologub et al., 2009) with modifications using a variant of Δ43 mtRNAP having an 
NG pair (hydroxylamine cleavage site) at position 150 and an engineered PKA site 
(Morozov et al., 2014). Specifically, 2 - 10 ml of the cross-linked material was lyophilized, 
dissolved in 30 ml of a solution containing 2 M NH2OH, 0.2 M Na2CO3 and 4 M Guanidine 
(pH 10-11.5 adjusted with 50% NaOH), and incubated for 4 h at 43°C. The reaction was 
stopped by addition of 70 μl of H2O and 400 ml of acetone, the products precipitated for 30 
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min at -70 °C, re-suspended in SDS gel loading buffer and resolved in 4 - 12% SDS-PAGE 
(Invitrogen).
Pyrophosphorolytic assay
The ECs (250 μM) were assembled using 32P-labeled RNA10, TS1 and NT1 for 10 min at 
RT in the presence or absence of TEFM (500 μM). The sequence of the oligos (IDTDNA) is 
as follows (5′ to 3′): CUGCGCGCAU (RNA10), 
GGGTCCTGTCTGAAATCGACATCGCCGC (TS1) and CGATTTCAGACAGGACCC 
(NT1). The reactions were incubated with pyrophosphate (50-500 μM) for 30 min at RT and 
stopped by the addition of formamide / EDTA containing buffer. The samples were resolved 
by electrophoresis in 20% PAGE in the presence of 6 M urea and visualized by 
PhosphoImager.
Analytical size-exclusion chromatography—The mitochondrial initiation complex 
was assembled by incubating Δ119 mtRNAP (20 μM) with the LSP promoter template 
(NT_LSP, TS_LSP) (20 μM), Δ42 “cys-less” TFAM (20 μM) and Δ20 TFB2M (40 μM) for 
10 min at 20°C. The sequence of the oligos (IDTDNA) is as follows (5′ to 3′): 
TGTTAGTTGGGGGGTGACTGTTAAAAGTGCATACCTATCCCCGATAGGCC 
(NT_LSP) and 
GGCCTATCTTTTGGCGGTATGCACTTTTAACAGTCACCCCCCAACTAACA 
(TS_LSP). To analyze binding of TEFM, WT TEFM (60 μM) was added to the initiation 
complex and incubated for 10 min at 20°C. Gel-filtration was performed us ing a Superdex 
200 Increase 3.2/300 size exclusion column (GE Healthcare) equilibrated with buffer 
containing 20 mM Tris-HCl pH 8.0, 100 mM NaCl, 20 mM MgCl2, and 2 mM DTT. For the 
dimer mutant analysis, the ECs (20 μM) were assembled using RNA14HH/TS22HH/
NT25HH scaffold (1.1-fold molar excess) for 10 min at 20°C. After incubation, the ECs 
were mixed with 2.2-fold molar excess of WT TEFM or TEFM mutant (F244E L248D 
I252D M256S L260D) and incubated for 10 min at 20°C. Gel-filtration was performed using 
a Superdex 200 Increase 3.2/300 size exclusion column (GE Healthcare) equilibrated with 
buffer containing 20 mM Tris-HCl pH 8.0, 200 mM NaCl, 20 mM MgCl2, 10 mM DTT and 
1 mM Tris(2-carboxyethyl)phosphine.
Data Availability
Atomic coordinates and structure factors for crystal structures of TEFM NTD, TEFM CTD 
and EC-TEFM complex have been deposited in the Protein Data Bank under ID codes 
5OL9, 5OL8 and 5OLA.
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Highlights
- Structure of human TEFM reveals a pseudo-nuclease core with two globular 
HhH-domains
- TEFM binding to the elongation complex of mtRNAP forms a ‘sliding clamp’
- Sliding clamp dramatically increases processivity of the elongation complex
- TEFM prevents G-quadruplex formation, driving transcription over mtDNA 
replication
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Figure 1. Crystal structure of human TEFM
(A) Schematic representation of human TEFM with residue numbers indicated. Domains 
identified by sequence-based homology prediction are depicted in different colors: 
mitochondrial targeting sequence (MTS): blue; N-terminal domain (NTD): orange; C-
terminal domain (CTD): raspberry, inter-domain linker: gray.
(B). A ribbon model of TEFM with the major domains and structural elements indicated. 
The C-terminal dimeric domain (CTD) is in brown/raspberry, the N-terminal domains 
(NTD) in orange. The inter-domain linker is represented by a dashed, grey line.
(C). Schematics of the primary and secondary structures of TEFM.
(D). Structural alignment of TEFM CTD (raspberry) and fission yeast Holliday junction 
resolvase Cce1 (PDB ID 1KCF) (grey).
(E). Structural alignment of TEFM NTD (orange) and bacterial (P. aeroginosa) transcription 
factor TEX (PDB ID 3BZC) (cyan). See also Table S1, Figure S1
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Figure 2. Functional role of TEFM domains
(A) Schematic representation of the TEFM NTD truncation mutants and inter-domain linker 
substation mutants used. Residues substituted are underlined with a black bar and the 
replacing residues are shown in blue beneath.
(B) TEFM CTD with the linker are required for anti-termination activity. Transcription 
assays were performed using a PCR template containing LSP and the CSBII region. The 
control reaction (lane 1) contains no TEFM. The reaction products were resolved using 20% 
PAGE containing 6M Urea.
(C, D) Anti-termination activity of TEFM variants having substitutions in the inter-domain 
linker.
(E) The NTD of TEFM is not required for the EC stability. The ECs assembled in the 
presence or absence of TEFM variants were halted 35 nt downstream of the transcription 
start site by omitting CTP. Upon incubation, the complexes were chased with CTP and the 
products of the reaction resolved using 20% PAGE containing 6M Urea. The region of the 
gel containing the 35 nt RNA is shown.
(F). Only the CTD of TEFM is required for mtRNAP processivity. Transcription was 
performed using a linearized plasmid template containing the LSP promoter to generate 
∼4000 nt run-off product.
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Figure 3. Topology of the anti-termination complex
(A) TEFM protects 19-20 nt of RNA from RNase 1 cleavage in the EC-TEFM complex. The 
ECs were halted 35 bp downstream of the LSP promoter prior to RNase 1 treatment. 
Positions of the RNA markers (18 and 27 nt) are indicated by grey lines.
(B) TEFM protects the downstream and the upstream DNA in the EC. The EC was 
assembled using R14/TS26/NT26A scaffold in the absence or presence of TEFM prior to 
DNase I treatment. The length of the DNA markers (15 and 34 nt, the leftmost lane) is 
indicated. The grey bar represents the DNA region protected by TEFM.
(C) Schematics of the RNA and DNA protection regions (shown in grey) in the anti-
termination complex shown on scaffold used in (B). See also Figure S2
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Figure 4. Structure of the anti-termination complex
(A,B) TEFM binding to the EC. MtRNAP (ribbon model) is shown with the major domains 
colored: Thumb: bright orange; Palm: lime-green; NTD: grey; PPR: teal; Fingers domain: 
pink. RNA is shown in red, template DNA strand in blue, non-template DNA strand in cyan. 
Intercalating hairpin and specificity loop (modeled) of mtRNAP are highlighted in purple 
and yelloworange, respectively.
(C). Close-up view of the TEFM binding site at the intercalating hairpin of mtRNAP. TEFM 
is shown as surface representation. Conserved residues (yellow) in mtRNAP are shown as 
sticks.
(D) TEFM interacts with the RNA-DNA scaffold in the EC. TEFM (ribbon representation) 
binds at junctions of the RNA-DNA hybrid and interacts with downstream and upstream 
DNA. The +1 template DNA base is not paired to its non-template counterpart, indicating 
the post-translocated conformation state of the EC. Note the proximity of the inter-domain 
linkers (residues 149-159, yellow) to the DNA duplexes; positively charged residues 
implicated in interaction with DNA are shown as sticks.
(E,F) Orientation of the O/Y helices of the fingers domain of mtRNAP relative to the 3′ end 
of RNA in the post-translocated (E) and pre-translocated (F, PDB ID 4BOC) ECs.
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(G) Movement of the O/Y helixes in the fingers domain of mtRNAP accompanies formation 
of the EC and RNA translocation. MtRNAPs from the apo form (PDB ID 3SPA), pre-
translocated EC (PDB ID 4BOC) and post-translocated EC-TEFM (this work) were 
superimposed using the conserved palm domain (residues 643-1230).
(H) TEFM stabilizes the post-translocated state of the EC. A pyrophosphorolytic assay was 
performed using the EC (lanes 3-7) and the EC-TEFM complex (lanes 9-13). The control 
(lane 1) is the EC. The assembled complexes were nearly 100% active as evident by efficient 
extension of the RNA primer by GTP (lanes 2,8). See also Table S2, Figure S3, S4
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Figure 5. TEFM interactions revealed by cross-linking
(A) Interaction regions in TEFM and mtRNAP revealed by chemical cross-linking and mass 
spectroscopy. The TEFM CTD is shown as a ribbon model; mtRNAP is depicted 
schematically as a bar with the major domains indicated as in Figure 4A. Cross-linked 
residues in TEFM are shown as sticks (yellow), lines represent the respective target residues/
regions in mtRNAP. The colors of the lines indicate the cross-linking reagent used.
(B) TEFM interacts with the specificity loop and the intercalating hairpin of mtRNAP. The 
ECs were assembled using mtRNAP containing Bpa at the position indicated and 32P-
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labeled TEFM. The efficiency of cross-linking is indicated beneath the gel, size of molecular 
weight markers (kDa) is shown to the left of the gel.
(C) Bpa cross-link reveals interaction of the docking loop of TEFM with mtRNAP. The ECs 
were assembled using 32P-labeled mtRNAP and TEFM containing Bpa at positions 
indicated.
(D) Location of the mapped regions on EC-TEFM structure. Cross-linking sites on TEFM 
(surface representation) are highlighted in yellow, the specificity loop (modeled; ribbon 
view) of mtRNAP is shown in yelloworange. The N-terminal extension domain of mtRNAP 
implicated in cross-linking with the docking loop of TEFM is shown as a dash line 
(chartreuse). The RNA is extended by 9 nucleotides to indicate a probable RNA exit channel 
according to the RNA cross-linking data (Agaronyan et al., 2015; Schwinghammer et al., 
2013).
(E,F) TEFM can efficiently cross-link only to the EC. Cross-linking was performed using 
32P-labelled TEFM, 1088Bpa-mtRNAP (E) or 610Bpa-mtRNAP (F). The reaction mixtures 
contained mtRNAP (apo, lane 2), mtRNAP, TFAM and LSP (pre-initiation complex, lane 3), 
mtRNAP, TFAM, TFB2M and LSP (initiation complex, lane 4) or mtRNAP and RNA/DNA 
scaffold (EC, lane 5). The control reaction (lane 1) contained TEFM only. See also Figure 
S5, S6
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Figure 6. Mechanism of transcription termination at CSBII
(A) Schematics of the RNA transcript encoded in the CSBII region in human mitochondria. 
The G-quadruplex region (G6AG8 variant) is highlighted in red, the points of termination 
are indicated by asterisks.
(B) Schematic depiction of a possible RNA G-quadruplex structure having a single 
nucleotide bulge.
(C) The spacer region of CSBII is dispensable for termination of transcription. Transcription 
assays were performed using promoter templates with the WT and mutated CSBII sequence, 
in which the spacer region was deleted.
(D) The U-run encoded in the CSBII region is required for transcription termination. The 
transcription assay was performed using the WT and modified CSBII sequence (GC≫AT), 
in which the AT-rich sequence proximal to the termination site was substituted to the GC-
rich sequence.
(E) RNA G-quadruplex structure clashes with the specificity loop and intercalating loop of 
mtRNAP. The model is obtained by extending the RNA in mtRNAP EC with the 16 
nucleotide-long G-quadruplex (PDB ID 2M4P). The G-quadruplex (red) is shown formed in 
vicinity of the trailing edge of transcription bubble in EC (surface representation). The 
specificity loop is modeled based on TEFM-mtRNAP Bpa cross-linking data.
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(F) Structure of the anti-termination complex (surface representation). Coloring as in Figure 
4A. See also Figure S7
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Figure 7. Target specificity of TEFM
(A,B) TEFM is a pseudo-resolvase. Putative active sites of human TEFM (A) and fission 
yeast Holliday junction resolvase Cce1 (B) are shown in similar orientation (ribbon 
representation). One of the magnesium-coordinating residues involved in catalysis in Cce1, 
D46, is replaced by the conserved residue V174 in TEFM. Two arginine residues conserved 
in all TEFM (R278 and R293, red sticks) are engaged in salt bridges with E232 and D342, 
effectively neutralizing their negative charge required for metal ion binding. An additional 
positive charge is contributed by K310 from the docking loop of a crystallographically 
related TEFM molecule (grey).
(C) Schematics of the transcription cycle in human mitochondria. During initiation, 
mtRNAP is recruited to promoter by interactions with TFAM. Subsequent binding of 
TFB2M results in formation of the initiation complex. Transition to the elongation phase of 
transcription occurs upon release of TFB2M and recruitment of TEFM, required for 
processive elongation. At the end of the transcription cycle, mtRNAP dissociates from 
mtDNA, which triggers release of TEFM. Structures shown are of TFAM/LSP (PDB ID 
3TMM (Ngo et al., 2011; Rubio-Cosials et al., 2011), the IC and the TFB2M models 
(Morozov et al., 2015), EC (PDB ID 4BOC) (Schwinghammer et al., 2013), EC-TEFM (this 
work) and apo mtRNAP (PDB ID 3SPA) (Ringel et al., 2011).
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